Recursion Pharmaceuticals, Inc. (RXRX) Revenue & EPS Growth Rates 2026 | EvidInvest

Growth Analysis - RXRX

Financial Metrics

Revenue Trends

Period:

CAGR Performance

Revenue

1Y Growth26.92%

5Y CAGR85.36%

10Y CAGRN/A

Net Income

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EPS

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBIT

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

EBITDA

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Capex

1Y Growth-52.76%

5Y CAGR-0.80%

10Y CAGRN/A

Equity

1Y Growth9.29%

5Y CAGRN/A

10Y CAGRN/A

Cash Flow

1Y GrowthN/A

5Y CAGRN/A

10Y CAGRN/A

Historical CAGR

Year	1Y CAGR	2Y CAGR	3Y CAGR	5Y CAGR	10Y CAGR	15Y CAGR	20Y CAGR	30Y CAGR
FY 2025 Dec 31, 2025	26.9%	29.4%	23.5%	85.4%	N/A	N/A	N/A	N/A
FY 2024 Dec 31, 2024	32.0%	21.8%	80.5%	102.9%	N/A	N/A	N/A	N/A
FY 2023 Dec 31, 2023	12.3%	111.1%	135.5%	N/A	N/A	N/A	N/A	N/A
FY 2022 Dec 31, 2022	296.8%	241.0%	185.2%	N/A	N/A	N/A	N/A	N/A
FY 2021 Dec 31, 2021	193.0%	141.8%	N/A	N/A	N/A	N/A	N/A	N/A
FY 2020 Dec 31, 2020	99.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2019 Dec 31, 2019	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Growth Analysis - RXRX

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Recursion Pharmaceuticals, Inc.

Compare with peers

Explore

Growth Analysis - RXRX

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Recursion Pharmaceuticals, Inc.

Compare with peers

Explore